

## Reaction of Malonaldehyde with Nucleic Acid. IV.<sup>1,2)</sup> Formation of Pyrimido[1,2-*a*]purin-10(3*H*)-one Nucleoside by Thermal Decomposition of Diastereomers Containing Oxadiazabicyclononene Residues Linked to Guanosine

Hiroshi SETO,\* Takako SETO, Tomoko OHKUBO and Ikue SAITOH

Tokyo Metropolitan Research Laboratory of Public Health, Hyakunincho 3-24-1, Shinjuku-ku, Tokyo 169, Japan. Received May 11, 1990

The reaction of 1,1,3,3-tetraethoxypropane with guanosine under strongly acidic conditions resulted in the formation of diastereomeric oxadiazabicyclononene residues linked to guanine base. The diastereomers were decomposed by heat, giving changed pyrimido[1,2-*a*]purin-10(3*H*)-one nucleoside (3) in a good yield. A convenient method for the preparation of 3, which includes the thermal decomposition process of the diastereomers, was developed.

**Keywords** malonaldehyde; guanosine; pyrimidopurine; 1,1,3,3-tetraethoxypropane; lipid peroxidation; diastereomeric adduct; thermal decomposition

Malonaldehyde (1), a product of lipid peroxidation and prostaglandin biosynthesis,<sup>3)</sup> is not only mutagenic<sup>4)</sup> but also carcinogenic.<sup>5)</sup> Exposure of humans to 1 may be considerable because of the abundance of 1 as a product of normal metabolism and in a variety of foodstuffs. Malonaldehyde is reactive toward amino groups of proteins<sup>6)</sup> and nucleic acids,<sup>7)</sup> even *in vivo*. Fluorescent adducts, pyrimido[1,2-*a*]purin-10(3*H*)-one homologues, have been separated from the reaction mixture of 1 with guanosine (2)<sup>8)</sup> or RNA<sup>9)</sup> under mild conditions (pH 4.5). The adduct, pyrimido[1,2-*a*]purin-10(3*H*)-one nucleoside (3), may have some biological activities. The yield of this adduct was very low (1.4%)<sup>8)</sup>; however, the amount of the compound preparable was insufficient for pharmacological and biological tests. The reaction conditions were investigated in order to improve the yield, and the diastereomeric products (4a, 4b) by the reaction of 2 with 1,1,3,3-tetraethoxypropane as a generator of 1 were obtained. Each adduct, 4a and 4b was identical with 5,6,7,8-tetrahydro-11-formyl-3(β-D-ribofuranosyl)-6,8-epoxyethenopyrimido[1,2-*a*]purin-10(3*H*)-one which was reported by Marnett *et al.*<sup>10)</sup> Both 4a and 4b are decomposed by heat, yielding 3 in a good yield. This is a simple and effective method for the preparation of 3.

This paper describes the preparation of the diastereomers (4a, 4b) and the straightforward preparation of 3 through the thermal decomposition process of 4a and 4b.

### Experimental

**Apparatus** Melting points are uncorrected. Optical rotations were measured with a JASCO DIP 181 polarimeter. IR, UV and CD spectra were recorded on Perkin-Elmer 1640, Shimadzu UV 240 and JASCO J-40A spectrophotometers, respectively. NMR spectra were obtained on a JEOL FX-270 spectrometer with 1,4-dioxane as an internal standard in D<sub>2</sub>O or with TMS in DMSO-*d*<sub>6</sub> at room temperature. FAB mass spectra (glycerol matrix) were recorded on a JEOL DX 303 mass spectrometer. Analytical HPLC was carried out with a JASCO 880PU equipped with a three-dimensional detector (Hewlett-Packard HP 1040M) on a Nucleosil 7C18 (Nagel, 4.6 i.d. × 250 mm) column (the mobile phase was 7% (v/v) acetonitrile/water). Preparative HPLC was carried out with a Milton Roy Constametric III pump equipped with a UV detector (Oyobunko Kiki Uvilog II, cell length 1 mm).

**Synthesis and Isolation of 3, 4a and 4b** All reagents were purchased from commercial sources. Guanosine (2) (5.56 g, 0.02 mol) was dissolved in 100 ml of 0.05 M HCl at 50 °C. 1,1,3,3-Tetraethoxypropane (11.0 g, 0.05 mol) was added to the guanosine solution. The reaction mixture was kept at 50 °C with stirring for 2 h, then concentrated to about 50 ml at 35 °C. It was subjected to polyamide column chromatography (Wako Pure Chemicals C-200, 50 i.d. × 350 mm) and eluted with 500 ml of water. The

eluate was concentrated to about 50 ml. The solution was injected little by little to a Lichroprep RP-18 (Merck, 22 i.d. × 300 mm) HPLC column and chromatographed with 7% (v/v) acetonitrile/water as the eluent. The fractions of 3, 4a and 4b were collected and concentrated to about 50 ml. The solution was applied little by little to an Inertsil ODS-2 column (Gasukuro Kogyo, 5 μm, 7.6 i.d. × 250 mm, 3% (v/v) acetonitrile/water). The final chromatography was carried out repeatedly more than 500 times. Each product solution was evaporated to dryness *in vacuo*.

Compound 3 (p3): mp > 195 °C (dec.). UV λ<sub>max</sub><sup>H<sub>2</sub>O</sup> nm (ε): 250 (13000), 308 (2770), 319 (3100), 348 (2700). EI MS *m/z*: 535 (C<sub>13</sub>H<sub>10</sub>N<sub>5</sub>O<sub>5</sub>(TMS)<sub>3</sub> M<sup>+</sup>). <sup>1</sup>H-NMR (D<sub>2</sub>O) δ: 3.89 (2H), 4.24 (1H), 4.45 (1H), 4.76 (1H), 6.02 (1H, d, *J* = 5.3 Hz), 7.34 (1H, dd, *J* = 4.0, 7.30 Hz), 8.31 (1H), 8.98 (1H, dd, *J* = 2.1, 3.8 Hz), 9.22 (1H, dd, *J* = 2.0, 7.3 Hz). Yield, 35 mg.

Compound 4a (p1): mp > 160 °C (dec.); [α]<sub>D</sub><sup>20</sup> -140° (*c* = 0.4, water). UV λ<sub>max</sub><sup>H<sub>2</sub>O</sup> nm (ε): 249 (20100). IR (KBr): 3329, 1700, 1620, 1560 cm<sup>-1</sup>. High-resolution FAB MS: Calcd for C<sub>16</sub>H<sub>18</sub>N<sub>5</sub>O<sub>7</sub> (M + H<sup>+</sup>) *m/z*: 392.1206. Found *m/z*: 392.1185. CD (*c* = 0.11 mM, water) [θ]<sub>D</sub><sup>22</sup> (nm): 0 (310), -45500 (282), 0 (269), +116000 (256), 0 (246), -102000 (237), 0 (219). <sup>1</sup>H-NMR (D<sub>2</sub>O) δ: 2.14 (1H, d, *J* = 14.5 Hz), 2.28 (1H, d, *J* = 14.5 Hz), 3.81 (2H, m), 4.17 (1H, m), 4.39 (1H, m), 4.70 (1H, m), 5.87 (1H, d, *J* = 5.9 Hz), 5.97 (1H, m), 6.15 (1H, m), 7.78 (1H, s), 7.97 (1H, s), 9.15 (1H, s). <sup>13</sup>C-NMR (DMSO-*d*<sub>6</sub>) δ: 23.5 (t), 33.6 (d), 61.2 (t), 70.3 (d), 73.4 (d), 76.2 (d), 85.1 (d), 86.2 (d), 117.0 (s), 119.8 (s), 136.3 (d), 148.5 (s), 148.6 (s), 153.8 (s), 163.7 (d), 188.2 (d). Yield, 200 mg.

Compound 4b (p2): mp > 160 °C (dec.); [α]<sub>D</sub><sup>20</sup> +111° (*c* = 0.4, water). UV λ<sub>max</sub><sup>H<sub>2</sub>O</sup> nm (ε): 249 (19800). IR (KBr): 3287, 1701, 1618, 1561 cm<sup>-1</sup>. High-resolution FAB MS: Calcd for C<sub>16</sub>H<sub>18</sub>N<sub>5</sub>O<sub>7</sub> (M + H<sup>+</sup>) *m/z*: 392.1206. Found *m/z*: 392.1190. CD (*c* = 0.11 mM, water) [θ]<sub>D</sub><sup>22</sup> (nm): 0 (310), +43200 (282), 0 (269), -118000 (256), 0 (246), +114000 (237), 0 (219). <sup>1</sup>H-NMR (D<sub>2</sub>O) δ: 2.14 (1H, d, *J* = 14.5 Hz), 2.27 (1H, d, *J* = 14.5 Hz), 3.80 (2H, m), 4.18 (1H, m), 4.37 (1H, m), 4.67 (1H, m), 5.85 (1H, d, *J* = 5.6 Hz), 5.97 (1H, m), 6.14 (1H, m), 7.76 (1H, s), 7.97 (1H, s), 9.14 (1H, s). <sup>13</sup>C-NMR (DMSO-*d*<sub>6</sub>) δ: 23.6 (t), 33.6 (d), 61.3 (t), 70.3 (d), 73.8 (d), 76.2 (d), 85.2 (d), 86.3 (d), 116.9 (s), 119.8 (s), 136.1 (d), 148.5 (s), 148.7 (s), 153.8 (s), 163.7 (d), 188.2 (d). Yield, 200 mg.

**Reaction of Malonaldehyde with Pyrimido[1,2-*a*]purin-10(3*H*)-one Nucleoside (3)** Malonaldehyde sodium salt<sup>11)</sup> (1 mg) and 3 (1 mg) were dissolved in 0.2 ml of 0.05 M HCl. The reaction mixture was maintained for 1 h at 50 °C. The mixture was neutralized by 0.05 M NaOH. Product analysis of the mixture was carried out by the HPLC method. The product (4a, 4b) was identified by both the UV spectrum and the retention time.

**Thermal Decomposition of 4a and 4b** A mixture of the diastereomers (4a, 5 mg and 4b, 5 mg) in a glass test tube was heated at 160 °C in an oil bath for 1 h. The product was dissolved in water (1 ml). An aliquot of the solution was chromatographed repeatedly on the Inertsil ODS-2 column with 5% (v/v) acetonitrile/water as the eluent. The fractions including 3 were collected and dried *in vacuo*. Yield, 5 mg (60%). The UV spectrum obtained was identical to that of authentic 3.

**Simplified Method for Preparation of 3 from Guanosine** The mixture of guanosine (2) (56 mg) and 1,1,3,3-tetraethoxypropane (110 mg) in 5 ml of 0.05 M HCl was stirred at 50 °C for 3 h. The solution was neutralized with 1 M NaOH. The neutral solution was applied to a polyamide gel column (20 i.d. × 300 mm, water as the eluent). The eluate (20–150 ml) was evaporated to dryness *in vacuo*. The mixture of dry materials in a flask was heated at 160 °C in an oil bath for 1 h. The product (3) was extracted





Fig. 1. HPLC Chromatogram of Guanosine-malonaldehyde Reaction Mixture

Column, Nucleosil 7C18 (4.6 i.d.  $\times$  250 mm); mobile phase, 7% (v/v) acetonitrile/water 1 ml/min; detector, 254 nm.

from the residue with 5 ml of hot water (60°C). The extract was cleaned on a polyamide column (13 i.d.  $\times$  60 mm, water as the eluent). The eluate (0–20 ml) was concentrated to 5 ml. The solution was subjected to a Lichroprep RP-18 column and chromatographed with 7% (v/v) acetonitrile/water as the eluent (Fig. 2). The fractions of **3** (50–70 min) were collected and evaporated to dryness *in vacuo*. Yield 16 mg.

## Results and Discussion

**Preparation of the Diastereomers (4a and 4b)** Figure 1 shows an HPLC chromatogram of a reaction mixture of guanosine with 1,1,3,3-tetraethoxypropane as a generator of malonaldehyde. The least polar adduct (p3) was identified as **3** by spectroscopic analyses. p1 and p2 showed a UV maximum at 249 nm. These adducts were separated by repeated chromatography. Though the formation of the compounds (p1, p2) proceeded only in strongly acidic media, the adduct (**3**) seems most likely to be formed *in vivo*. In fact, detection and identification of pyrimido[1,2-*a*]purin-10(3*H*)-one (aglycone of the adduct (**3**)) actually formed *in vivo* has been carried out by Draper's group.<sup>12)</sup>

Adducts p1 and p2 were isolated as a white solid and 200 mg of each (purity 99%, HPLC) were obtained. They were not fluorescent and possessed UV, NMR, MS and CD spectral properties indicating the presence of oxadiazabicyclononene residues linked to guanosine, as reported by Marnett *et al.*<sup>10)</sup> Each adduct, p1 (**4a**) and p2 (**4b**) was deduced to 5,6,7,8-tetrahydro-11-formyl-3( $\beta$ -D-ribofuranosyl)-6,8-epoxyethenopyrimido[1,2-*a*]purin-10(3*H*)-one




Fig. 2. Preparative HPLC Chromatogram of the Solution Containing **3**

Column, Lichroprep RP-18 (22 i.d.  $\times$  300 mm); mobile phase, 7% (v/v) acetonitrile/water 5 ml/min; detector, 254 nm. Details about the sample are described in the text.

(Chart 1). There were two isomers, namely (6*R*,8*R*)- and (6*S*,8*S*)-. Since spectroscopic details about p1 and p2 were not exhibited in a distinguishable form,<sup>10)</sup> we listed the data in the experimental section. As shown in Chart 1, the isomers were formed by the addition of a second molecule of **1** to **3** and were easily cleaved by alkali (0.01 M NaOH) into **1** and **2** (data not shown).

**Formation of Pyrimido[1,2-*a*]purin-10(3*H*)-one Nucleoside (**3**) by Thermal Decomposition of **4a** and **4b**** Both **4a** and **4b** were decomposed by heat, yielding **3**. Heating of 10 mg of the isomers at 160°C for 1 h gave **3** in a 60% yield. The product (**3**) was isolated (5 mg) by HPLC and identified by means of UV spectral comparison.

Based on these results, we proposed a convenient method which includes a thermal decomposition process of **4a** and **4b** for the preparation of **3**.

**Preparation of **3** from **2** by the Proposed Method Including the Thermal Decomposition Process of **4a** and **4b**** The product (**3**) was obtained in a 25% yield (16 mg of **3** from 56 mg of **2**) by use of the proposed method in this work (Fig. 2). When the preparation of **3** was carried out without the heating process, only 4 mg (6%) of product (**3**) was obtained. The heating process for the decomposition of **4a** and **4b** is necessary to improve the yield of **3**. In contrast, the reaction of **1** with **2** under a higher pH condition (pH 4.5) produced **3** in only a 1.4% yield.<sup>8)</sup>

The rate of formation of 7-alkyl pyrimido[1,2-*a*]purin-10(3*H*)-one on the reaction of 2-alkyl malonaldehyde with guanine was high in a low pH medium.<sup>13)</sup> However, as the pH lowered (0.05 M HCl) in the reaction of non-substituted malonaldehyde (**1**) with guanosine (**2**), formation of **4a** and **4b** seemed to be dominant compared to that of **3** (Fig. 1). Our results showed that **3** was the intermediate, and **4a** and **4b** the ultimate, products in the successive reaction. Fortunately, it is possible to obtain **3** in a good yield by use of the thermal decomposition process of **4a** and **4b**. In addition, it took 10 d for a reaction in the previous work.<sup>8)</sup> Our proposed method requires only 3 h for the liquid phase reaction and 1 h for the heating process.

The proposed method, which includes the thermal decomposition process of **4a** and **4b**, is rapid and effective for the preparation of **3**.

**Acknowledgements** We are grateful to Mr. K. Matsuura, JEOL Ltd., for measurements of FAB MS. We also thank Mr. Y. Hiraoka and Mr. R. Inomata for excellent technical assistance.

#### References and Notes

- 1) Part III: H. Seto, T. Seto, T. Takesue and T. Ikemura, *Chem. Pharm. Bull.*, **34**, 5079 (1986).
- 2) Abbreviations used are as follows: RNA, ribonucleic acid; HPLC, high-performance liquid chromatography; UV, ultraviolet; NMR, nuclear magnetic resonance; MS, mass spectrometry; CD, circular dichroism; FAB, fast atom bombardment; EI, electron impact; TMS, tetramethylsilane; DMSO, dimethyl sulfoxide
- 3) W. A. Pryor, "Free Radicals in Biology," Vol. 1 and Vol. 4, Academic Press, New York, 1976.
- 4) a) F. H. Mukai and B. D. Goldstein, *Science*, **191**, 868 (1976); b) A. K. Basu and L. J. Marnett, *Carcinogenesis*, **4**, 331 (1983); c) P. E. Hartman, *Environ. Mutagen*, **5**, 603 (1983).
- 5) a) R. J. Shamberger, T. L. Andreone and C. E. Willis, *J. Natl. Cancer Inst.*, **53**, 1771 (1974); b) R. P. Bird, H. H. Draper and V. E. O. Valli, *J. Toxicol. Environ. Health*, **10**, 897 (1982).
- 6) a) K. S. Chio and A. L. Tappel, *Biochemistry*, **8**, 2821 (1969); b) H. W. Gardner, *J. Agric. Food Chem.*, **27**, 220 (1979); c) H. H. Draper, M. Hadley, L. Lissemore, N. M. Laing and P. D. Cole, *Lipids*, **23**, 626 (1988).
- 7) a) U. Reiss, A. L. Tappel and K. S. Chio, *Biochem. Biophys. Res. Commun.*, **48**, 921, (1972); b) K. Kikugawa, K. Taguchi and T. Maruyama, *Chem. Pharm. Bull.*, **35**, 3364 (1987).
- 8) a) H. Seto, K. Akiyama, T. Okuda, T. Hashimoto, T. Takesue and T. Ikemura, *Chem. Lett.*, **1981**, 707; b) H. Seto, T. Okuda, T. Takesue and T. Ikemura, *Bull. Chem. Soc. Jpn.*, **56**, 1799 (1983).
- 9) H. Seto, Y. Takesue and T. Ikemura, *Bull. Chem. Soc. Jpn.*, **58**, 3431 (1985).
- 10) a) L. J. Marnett, A. K. Basu, S. M. O'Hara, P. E. Weller, A. F. M. Maqsdur Rahman and J. P. Oliver, *J. Am. Chem. Soc.*, **108**, 1348 (1986); b) A. K. Basu, S. M. O'Hara, P. Vallandier, K. Stone, O. Mols and L. J. Marnett, *Chem. Res. Toxicol.*, **1**, 53 (1988).
- 11) L. J. Marnett and M. A. Tuttle, *Cancer Res.*, **40**, 276 (1980).
- 12) M. Hadley and H. H. Draper, *Lipid*, **25**, 82 (1990).
- 13) R. C. Moschel and N. J. Leonard, *J. Org. Chem.*, **41**, 294 (1976).